| BioWorld

Resolvyx Adds $25M to Move First Resolvin Drugs into Clinic

Gearing up to move its first two drug candidates into the clinic this year, Resolvyx Pharmaceuticals Inc. padded its bank account with a $25 million Series B round from new and existing investors. (BioWorld Today) Read More

Congress Told Foreign Plants are 'Ticking Time Bombs'

'Pseudokinase' Found Active, Without Binding Magnesium

CuraGen Sells Cancer Drug to TopoTarget for $45M

Genzyme Must File 2 BLAs for Myozyme Formulations

Theravance Cuts Staff 40%; Telavancin Inches Along

FDA Approves Cimzia for Crohn's Disease

Spectrum Shares Falls on Ozarelix Miss

ImClone, BioVex Secure SPAs For Late-Stage Cancer Studies

Other News To Note

Clinic Roundup

BioWorld

April 23, 2008

Resolvyx Adds $25M to Move First Resolvin Drugs into Clinic

Congress Told Foreign Plants are 'Ticking Time Bombs'

'Pseudokinase' Found Active, Without Binding Magnesium

CuraGen Sells Cancer Drug to TopoTarget for $45M

Genzyme Must File 2 BLAs for Myozyme Formulations

Theravance Cuts Staff 40%; Telavancin Inches Along

FDA Approves Cimzia for Crohn's Disease

Spectrum Shares Falls on Ozarelix Miss

ImClone, BioVex Secure SPAs For Late-Stage Cancer Studies

Other News To Note

Clinic Roundup

Today's news in brief

Today's news in brief

News in brief

Exercise-mimicking compound offers alternative to GLP-1 therapies

Moderna expands mRNA tech to latent viruses, cancer, rare disease